Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

被引:87
作者
Bymaster, FP [1 ]
Falcone, JF [1 ]
Bauzon, D [1 ]
Kennedy, JS [1 ]
Schenck, K [1 ]
DeLapp, NW [1 ]
Cohen, ML [1 ]
机构
[1] Lilly Corp Ctr, Lilly Res Labs, Neurosci Res Div, Indianapolis, IN 46285 USA
关键词
olanzapine; risperidone; quetiapine; ziprasidone; 5-HT3; receptor; 5-HT6;
D O I
10.1016/S0014-2999(01)01399-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The interaction of the psychotropic agent olanzapine with serotonin 5-HT3 and 5-HT6 receptors was investigated. Olanzapine did not contract the isolated guinea pig ileum, but blocked contractions induced by the 5-HT3 receptor agonist 2-methyl serotonin (2-CH3 5-HT) with a pK(B) value of 6.38 +/- 0.03, close to the affinity of the 5-HT3 receptor antagonist ondansetron. The atypical antipsychotic risperidone (1 muM) did not significantly inhibit 2-CH3 5-HT-induced contractions. Olanzapine had high affinity (pK(i) = 8.30 +/- 00.06) for human 5-HT6 receptors in radioligand binding studies. Olanzapine did not stimulate [S-35]guanosine-5'-O-(3-thio)triphosphate ([S-35]GTP gammaS) binding to the G protein G, in cells containing human 5-HT6 receptors, but inhibited 5-HT-stimulated [S-35]GTP gammaS binding (pK(B) = 7.38 +/- 0.16). Among other antipsychotics investigated, clozapine antagonized 5-HT6 receptors with a pK(B) = 7.42 +/- 0.15, ziprasidone was three-fold less potent, and risperidone, quetiapine and haloperidol were weak antagonists. Thus, olanzapine was not an agonist, but was a potent antagonist at 5-HT6 receptors and had marked antagonism at 5-HT3 receptors. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:341 / 349
页数:9
相关论文
共 66 条
[1]   Tardive dyskinesia as a result of long-term prochlorperazine use [J].
Alberts, VA ;
Catalano, G ;
Poole, MA .
SOUTHERN MEDICAL JOURNAL, 1996, 89 (10) :989-991
[2]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[3]   Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers [J].
Benedict, CR ;
Arbogast, R ;
Martin, L ;
Patton, L ;
Morrill, B ;
Hahne, W .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 28 (01) :53-59
[4]   OLANZAPINE, AN ATYPICAL ANTIPSYCHOTIC, INCREASES RATES OF PUNISHED RESPONDING IN PIGEONS [J].
BENVENGA, MJ ;
LEANDER, JD .
PSYCHOPHARMACOLOGY, 1995, 119 (02) :133-138
[5]   Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells [J].
Boess, FG ;
Monsma, FJ ;
Carolo, C ;
Meyer, V ;
Rudler, A ;
Zwingelstein, C ;
Sleight, AJ .
NEUROPHARMACOLOGY, 1997, 36 (4-5) :713-720
[6]   Involvement of 5-HT6 receptors in nigro-striatal function in rodents [J].
Bourson, A ;
Boess, FG ;
Bös, M ;
Sleight, AJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (07) :1562-1566
[7]   5-HT6 receptors as emerging targets for drug discovery [J].
Branchek, TA ;
Blackburn, TP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2000, 40 :319-334
[8]   THE PHARMACOLOGICAL CHARACTERIZATION OF 5-HT3 RECEPTORS IN 3 ISOLATED PREPARATIONS DERIVED FROM GUINEA-PIG TISSUES [J].
BUTLER, A ;
ELSWOOD, CJ ;
BURRIDGE, J ;
IRELAND, SJ ;
BUNCE, KT ;
KILPATRICK, GJ ;
TYERS, MB .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 101 (03) :591-598
[9]   Olanzapine: a basic science update [J].
Bymaster, F ;
Perry, KW ;
Nelson, DL ;
Wong, DT ;
Rasmussen, K ;
Moore, NA ;
Calligaro, DO .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :36-40
[10]   Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium [J].
Bymaster, FP ;
Falcone, JF .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 390 (03) :245-248